1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,550 | 5,590 | 18.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | - | HKEx | ||
| Mi | LEADS BIOLABS-B (09887): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 17, 2025 | - | HKEx | ||
| Mo | LEADS BIOLABS-B (09887): INSIDE INFORMATION - PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION PROGRAM BY THE COMPANY | 1 | HKEx | ||
| 01.12. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 RECEIVED IND APPROVAL FROM NMPA | 1 | HKEx | ||
| 28.11. | LEADS BIOLABS-B (09887): THE H SHARE AWARD SCHEME | - | HKEx | ||
| 28.11. | LEADS BIOLABS-B (09887): PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, DECEMBER 17, 2025 | 2 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 28.11. | LEADS BIOLABS-B (09887): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 28.11. | LEADS BIOLABS-B (09887): (1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME; (2) PROPOSED AUTHORIZATION TO THE BOARD OF DIRECTORS AND/OR THE DELEGATEE ... | - | HKEx | ||
| 27.11. | LEADS BIOLABS-B (09887): ANNOUNCEMENT BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 25.11. | LEADS BIOLABS-B (09887): (1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME; AND (2) PROPOSED CANCELLATION OF THE SUPERVISORY COMMITTEE AND PROPOSED AMENDMENTS ... | 2 | HKEx | ||
| 10.11. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE II TRIAL OF FIRST-LINE TREATMENT FOR HEPATOCELLULAR CARCINOMA | - | HKEx | ||
| 07.11. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE MSCI GLOBAL SMALL CAP INDEXES | 1 | HKEx | ||
| 03.11. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - FURTHER ANNOUNCEMENT ON RESEARCH ABSTRACTS ACCEPTED FOR PRESENTATION AT THE 67TH ASH ANNUAL MEETING | 1 | HKEx | ||
| 27.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE II TRIAL OF FIRST-LINE TREATMENT FOR BILIARY TRACT CANCER | 1 | HKEx | ||
| 17.10. | LEADS BIOLABS-B (09887): CLARIFICATION ANNOUNCEMENT | 1 | HKEx | ||
| 16.10. | LEADS BIOLABS-B (09887): (REVISED) INSIDE INFORMATION - EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH DIANTHUS FOR LBL-047 | - | HKEx | ||
| 16.10. | LEADS BIOLABS-B (09887): INSIDE INFORMATION - EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH DIANTHUS FOR LBL-047 | - | HKEx | ||
| 16.10. | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for ... | 180 | GlobeNewswire (Europe) | DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function... ► Artikel lesen | |
| 09.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT RESEARCH RESULTS OF TWO INNOVATIVE DRUGS TO BE PRESENTED AT THE 67TH ASH ANNUAL MEETING | 2 | HKEx | ||
| 26.09. | LEADS BIOLABS-B (09887): 2025 INTERIM REPORT | - | HKEx |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,445 | -0,09 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,14 | +0,35 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,900 | -3,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,440 | -5,23 % | What's Happening With RXRX Stock? | ||
| ATHIRA PHARMA | 6,740 | +62,41 % | Athira Pharma, Inc.: Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million | Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 30,740 | -5,62 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| EVOTEC | 5,144 | -0,50 % | Auf der Gewinnerseite - jetzt und in 2026: Antimony Resources und Bayer, Absturz bei Evotec! | Das Jahr geht bald zu Ende. Zeit, sich Aktien und Investmentthemen zu widmen, mit denen 2026 attraktive Renditen winken. Trends wie AI, Rüstung oder Robotik werden sich fortsetzen. Lukrativ erscheint... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 9,970 | +13,75 % | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 79,63 | -3,16 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| BIONTECH | 78,20 | +0,26 % | 60 Prozent Aufwärtspotenzial?: BioNTech: Diese Gamechanger sind noch nicht im Kurs eingepreist! | © Foto: Sebastian Gollnow/dpa Für Anleger von BioNTech gab es 2025 nicht viel zu feiern. Auf Jahressicht hat die Aktie rund 15 Prozent verloren. Dabei sind die großen Innovationen im Krebsbereich noch... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 21,170 | -5,07 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| IMMUNOME | 19,960 | +0,71 % | Immunome-Aktie fällt nach Ankündigung einer Kapitalerhöhung über 400 Mio. US-Dollar | ||
| APOGEE THERAPEUTICS | 77,35 | +2,41 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,785 | -1,85 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,000 | -0,05 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
NANJING LEADS BIOLABS CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,100 Euro und damit +27,47 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.